Healthcare Providers and Services
Company Overview of City Of Hope
City of Hope, a nonprofit public benefit corporation, operates City of Hope National Medical Center (the Center), City of Hope Medical Foundation, and Beckman Research Institute of the City of Hope. The Center operates a 186-bed tertiary referral center primarily for the treatment of cancer, diabetes, and other life-threatening diseases in Duarte, California. The company was founded in 1913 and is based in Duarte, California.
1500 East Duarte Road
Duarte, CA 91010
Founded in 1913
Key Executives for City Of Hope
Chief Executive Officer and President
Chief Operating Officer and Executive Vice President
Chief Scientific Officer and Provost
Senior Vice President of Research Operations
Compensation as of Fiscal Year 2014.
City Of Hope Key Developments
City of Hope and Fortress Biotech Reach an Agreement to Form New Subsidiary Company, Diavax Biosciences
May 4 15
City of Hope and Fortress Biotech have reached an agreement to form a new subsidiary company, DiaVax Biosciences, that will develop two novel vaccines against cytomegalovirus infection, a life-threatening illness in people with weakened or underdeveloped immune systems, such as cancer patients and developing fetuses. Enlisting the defensive power of the immune system, the vaccines could open the door to a new way of treating a devastating opportunistic infection affecting hundreds of thousands worldwide. The vaccines Triplex and PepVax will be the subject of multi-site Phase II clinical trials, one of which already has begun enrollment (PepVax). The other (Triplex) will begin enrollment in fall of 2015. Supported by the National Cancer Institute, those trials could ultimately lead to even greater impact for City of Hopeâ€™s research. DiaVax has entered into an option with City of Hope for exclusive worldwide rights to a universal immunotherapeutic vaccine, called Pentamer, that could prevent the transmission of CMV in utero. Such transmission leads to thousands of cases of irreversible brain damage every year.
Larry Kwak Will Join City of Hope to Head One of Six Cornerstone Centers in the Institution's
Feb 26 15
City Of Hope announced that Larry W. Kwak, M.D., Ph.D., will join City of Hope in a key leadership role within the institution's new Hematologic Malignancies and Stem Cell Transplantation Institute. As director of the Toni Stephenson Lymphoma Center, Kwak will shape the next generation of research and treatments for all types of lymphoma. Kwak joins City of Hope from M.D. Anderson Cancer Center in Houston, where he served as chairman of the Department of Lymphoma and Myeloma and as co-director of the Center for Cancer Immunology Research. At City of Hope, he will head one of six cornerstone centers in the institution's recently launched hematologic malignancies institute, setting scientific priorities and guiding the development of new approaches to treating lymphoma and related diseases, especially those involving immune-based treatments. Kwak will also serve in the dual leadership role of inaugural associate director for developmental therapeutics and translational research for City of Hope's National Cancer Institute-designated comprehensive cancer center and hold the title of the Dr. Michael Friedman Professor for Translational Medicine.
Guido Marcucci Joins City of Hope in Leadership Role
Jan 26 15
Guido Marcucci has joined City of Hope in a key leadership role within the institution’s new Hematologic Malignancies and Stem Cell Transplantation Institute. As Director of the Gehr Family Center for Leukemia Research and as Chief of the Division of Hematopoietic Stem Cell and Leukemia Research, Marcucci will guide research into improved treatments, even cures, for leukemia and other hematologic malignancies. Marcucci, who will also serve as a professor of Hematology & Hematopoietic Cell Transplantation, joins City of Hope from Ohio State University, where he was a professor of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, and Pharmaceutics in the Division of Hematology at the university’s Comprehensive Cancer Center. At City of Hope, he will head one of six cornerstone centers in the institution’s recently launched hematologic institute, setting scientific priorities and guiding the development of new approaches to treating leukemia and related diseases, especially those involving hematopoietic stem cell transplantation.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 26, 2014